Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics.
Journal
Methods (San Diego, Calif.)
ISSN: 1095-9130
Titre abrégé: Methods
Pays: United States
ID NLM: 9426302
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
18
06
2018
revised:
31
08
2018
accepted:
04
09
2018
pubmed:
13
9
2018
medline:
28
11
2019
entrez:
13
9
2018
Statut:
ppublish
Résumé
The immunoglobulin superfamily protein lymphocyte-activation gene 3 (LAG-3) participates in immune suppression and has been identified as a suitable target for cancer therapies. In order to generate bispecific antibodies targeting LAG-3, Fcabs (Fc-region with antigen binding) targeting human and murine LAG-3 were generated from phage libraries. These Fcabs bind to LAG-3, inhibiting its interaction with MHC class II, and induce IL-2 production in a T cell assay. Bispecific antibodies, known as mAb
Identifiants
pubmed: 30208333
pii: S1046-2023(18)30103-8
doi: 10.1016/j.ymeth.2018.09.003
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Antigens, CD
0
Immunoglobulin Fc Fragments
0
Lymphocyte Activation Gene 3 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-69Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.